MMV selects UCT developed anti-malaria molecule for clinical trials
The compound is expected to cure all strains of malaria and stop the transmission of the parasite from person to person as a single-dose malaria cure. The new
The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).